Fovea  Pharmaceuticals SA (Paris, France) has entered into a collaborative research  agreement with Genzyme Corporation (Cambridge, MA). The alliance is anchored  around Fovea’s proprietary high content technology platform that allows the  identification of new targets involved in photoreceptor degeneration in retinal  dystrophies. The companies will collaborate to develop gene related therapies  using Fovea selected targets and Genzyme gene delivery technologies.

  The ultimate  cause of irreversible blindness in major retinal diseases is photoreceptor  degeneration. According to the Foundation Fighting Blindness, rare inherited  retinal dystrophies like Stargardt’s disease or 

 are recognized as the most common inherited  causes of blindness in people below the age of 50, affecting approximately 1.5  million people worldwide. In addition, in more common retinal disorders like  the dry form of age related macular degeneration, sight loss ultimately results  from photoreceptor degeneration.

  In this  complementary partnership, Fovea’s scientific, clinical, and pharmaceutical  expertise in retinal diseases and Genzyme’s extensive know-how in protein  production and gene delivery will offer customized solutions for the  understanding of the disease mechanisms, with the goal to develop new  therapeutic strategies to prevent or reduce the severity of blindness.

News

Fovea Pharmaceuticals SA (Paris, France) has entered into a collaborative research agreement with Genzyme Corporation (Cambridge, MA). The alliance is anchored around Fovea's proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies.